RecruitingNot Applicable

Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease

China200 participantsStarted 2025-03-19

Plain-language summary

With the accelerating global aging population, dementia has become a pressing worldwide issue. This project aims to identify specific plasma biomarkers and ocular indicators for the early detection of Alzheimer's disease (AD).

Who can participate

Age range50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male or female participants aged ≥ 50 years; * Participants diagnosed with Alzheimer's Disease (AD), mild cognitive decline (MCI), subjective cognitive decline (SCD), or cognitively normal (CN); * Signed informed consent form Exclusion Criteria: * Presence of other neurological disorders and systemic diseases that may cause cognitive impairment; * Inability to cooperate with cognitive assessments; * Refusal to undergo blood sampling.

What they're measuring

Differences in Multimodal Ophthalmic Imaging parameter values among groups

Timeframe: Baseline

Trial details

NCT IDNCT06924359

SponsorPeking University First Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-08-31

View on ClinicalTrials.gov More Alzheimer's Disease (AD) trials